MedTrace Logo

Immune Checkpoint Inhibitors and Pre-existing Autoimmune Diseases

NCT03140137 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 112

Last updated 2019-04-22

No results posted yet for this study

Summary

The tolerance of immune checkpoint inhibitors is unknown in patients with pre-existing autoimmune conditions. This retrospective nation-wide study will assess their tolerance in patients with pre-existing autoimmune conditions who received immune checkpoint inhibitors for an advanced cancer in clinical practice.

Conditions

Interventions

DRUG

Checkpoint inhibitor therapy

Treatment by ipilimumab, nivolumab or pembrolizumab for advanced cancer in clinical practice

Sponsors & Collaborators

  • University Hospital, Brest

    lead OTHER

Principal Investigators

  • Divi CORNEC · CHRU de Brest

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-21
Primary Completion
2018-01-04
Completion
2018-01-04

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03140137 on ClinicalTrials.gov